Ralph DeMasi

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America

Jacob Lalezari, Keith Henry, Mary O’Hearn et al. · New England Journal of Medicine · 2003 · 909 citations · Full text

Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia

Adriano Lazzarin, Bonaventura Clotet, David A. Cooper et al. · New England Journal of Medicine · 2003 · 651 citations · Full text

Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates

Prakash Sista, Tom Melby, Donna K. Davison et al. · AIDS · 2004 · 154 citations

Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials

Mark Nelson, Keikawus Arastéh, Bonaventura Clotet et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2005 · 150 citations

Short‐Term Safety and Antiretroviral Activity of T‐1249, a Second‐Generation Fusion Inhibitor of HIV

Joseph J. Eron, Roy M. Gulick, John Bartlett et al. · The Journal of Infectious Diseases · 2004 · 126 citations · Full text

Second‐generation Fusion Inhibitor, 39-Aa Synthetic Peptide, Hiv-1-infected Adults +14